ANI Pharmaceuticals (ANIP) said Monday it received the US Food and Drug Administration's approval for purified cortrophin gel (repository corticotropin injection USP) in a prefilled syringe format as multiple sclerosis therapy.
The gel will be available in various single-dose options through specialty pharmacy network, the company said late Monday. The prefilled syringe reduces "administration steps" for patients using the gel.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.